Bolden Therapeutics, a Providence, RI-based company developing therapeutics to promote neurogenesis for the potential treatment of central nervous system diseases, received an investment from LifeSpan Vision Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its R&D sector.
Co-founded by Dr. Justin Fallon and Dr. Ashley Webb and led by CEO Johnny Page, Bolden Therapeutics is a biotechnology company developing therapeutics to treat central nervous system diseases. It is currently working on antisense oligonucleotides for this genetically validated target, with candidates ready for in vivo efficacy testing.
Its research facilities are based within Tufts Launchpad | biolabs, an incubator for next-generation powerhouse biotech startups located in Boston, MA. Prior to moving to biolabs, Bolden was based at LabCentral and its tenure was supported by two ‘Golden Tickets’ from Biogen, providing the company with two years of sponsored laboratory space within that innovative ecosystem.
FinSMEs
09/01/2024